$18.55
0[0.00%]
At close: Apr 29
$18.55
0[0.00%]
PreMarket: 4:00PM EDT
Kiniksa Pharmaceuticals
(NASDAQ:KNSA)Latest News for Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)
Kiniksa Pharmaceuticals Stock (NASDAQ: KNSA)
Categories: All
Wednesday, April 24, 2024
Tuesday, April 23, 2024
- Kiniksa Expects 2024 Arcalyst Net Product Revenue Of $370M-$390M Compared To Prior Guidance Of $360M-$380MBenzinga Newsdesk - 6 days ago
- Kiniksa Pharmaceuticals Q1 2024 GAAP EPS $(0.25) Misses $(0.14) Estimate, Sales $79.858M Beat $78.460M EstimateBenzinga Newsdesk - 6 days ago
- Earnings Scheduled For April 23, 2024Benzinga Insights - Apr 23, 2024, 6:56AM
Wednesday, February 28, 2024
- Kiniksa Expects 2024 ARCALYST Net Product Revenue Of Between $360M-$380M; That Its Cash, Cash Equivalents, And Short-Term Investments Will Fund Its Current Operating Plan Into At Least 2027Benzinga Newsdesk - Feb 28, 2024, 7:31AM
- Kiniksa Pharmaceuticals Q4 EPS $0.35 Beats $(0.14) Estimate, Sales $83.39M Beat $72.02M EstimateHappy Mohamed - Feb 28, 2024, 7:31AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Thursday, January 04, 2024
Tuesday, January 02, 2024
Tuesday, October 31, 2023
Monday, October 30, 2023
Monday, September 11, 2023
Monday, August 21, 2023
Friday, July 28, 2023
Wednesday, July 26, 2023
Tuesday, July 25, 2023
- Crude Oil Up 1%; Verizon Earnings Beat ViewsLisa Levin - Jul 25, 2023, 2:31PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Jul 25, 2023, 1:31PM
- Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Jul 25, 2023, 1:11PM
- Kiniksa Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 results.Benzinga Newsdesk - Jul 25, 2023, 12:55PM
- Xerox, Logitech International, Packaging Corporation of America And Other Big Stocks Moving Higher On TuesdayLisa Levin - Jul 25, 2023, 10:22AM
- UPDATE: Kiniksa Pharmaceuticals Q2 Adj EPS $(0.02) Beats $(0.17) Estimate, Sales $71.47M Beat $52.20M EstimateHappy Mohamed - Jul 25, 2023, 8:10AM
- Kiniksa Forecasts Arcalyst Revenues Of $220M-$230M Compared To Prior Guidance Of $200M-$215M; Cash & Cash Equivalents Of $185M Is Expected To Provide Cash Runway Into 2027Benzinga Newsdesk - Jul 25, 2023, 7:35AM
- Kiniksa Pharmaceuticals Q2 Adj EPS $(0.02) Beats $(0.17) Estimate, Sales $71.47M Beat $52.20M EstimateBenzinga Newsdesk - Jul 25, 2023, 7:32AM
- Earnings Scheduled For July 25, 2023Benzinga Insights - Jul 25, 2023, 5:00AM
Monday, July 24, 2023
Monday, June 05, 2023
Monday, May 22, 2023
Thursday, March 09, 2023
Tuesday, February 28, 2023
- Kiniksa Pharmaceuticals Sees FY23 Net Product Revenue $190M-$205M Vs $239.17M EstHappy Mohamed - Feb 28, 2023, 8:12AM
- Kiniksa Pharmaceuticals Q4 EPS $0.06 Beats $(0.23) Estimate, Sales $61.88M Beat $45.11M EstimateHappy Mohamed - Feb 28, 2023, 8:10AM
- Earnings Scheduled For February 28, 2023Benzinga Insights - Feb 28, 2023, 4:34AM
Monday, January 09, 2023
Wednesday, November 02, 2022
Tuesday, November 01, 2022
- Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Nov 1, 2022, 12:38PM
- Kiniksa Pharmaceuticals shares are trading higher after the company reported Q3 EPS and sales results were higher year over year.Benzinga Newsdesk - Nov 1, 2022, 10:39AM
- Recap: Kiniksa Pharmaceuticals Q3 EarningsBenzinga Insights - Nov 1, 2022, 8:25AM
- Kiniksa Pharmaceuticals Q3 EPS $3.18 Up From $(0.44) YoY, Sales $33.42M Up From $12.10M YoYBenzinga Newsdesk - Nov 1, 2022, 8:19AM
Monday, October 24, 2022
Wednesday, August 03, 2022
- Kiniksa Inks Global License Agreement With Roche For VixarelimabVandana Singh - Aug 3, 2022, 9:40AM
- Kiniksa Pharmaceuticals: Q2 Earnings InsightsBenzinga Insights - Aug 3, 2022, 8:05AM
- Kiniksa Pharmaceuticals Q2 Sales $27.00M Up From $7.70M YoYBenzinga Newsdesk - Aug 3, 2022, 7:46AM
- Kiniksa Pharmaceuticals Announces Global License Agreement With Genentech For Vixarelimab; Co. To Receive $100M In Upfront And Near-Term Payments And Is Eligible For Up To $600M In MilestonesBill Haddad - Aug 3, 2022, 7:30AM